Expression of the Endostatin Gene in Epithelial Ovarian Cancer

Endostatin, a M r 20,000 COOH-terminal fragment of collagen XVIII, is currently in preclinical development as a novel antiangiogenic agent. The gene expression of this molecule in 23 normal ovaries with follicle or corpus luteum and in 64 cases of epithelial ovarian cancer (27 serous, 18 mucinous, 1...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2001-08, Vol.7 (8), p.2405-2409
Main Authors: HATA, Kohkichi, FUJIWAKI, Ritsuto, NAKAYAMA, Kentaro, MIYAZAKI, Kohji
Format: Article
Language:English
Subjects:
Biological and medical sciences
Collagen - genetics
Collagen Type XVIII
Endostatins
Female
Female genital diseases
Gene Expression Regulation, Neoplastic
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Neoplasm Staging
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Peptide Fragments - genetics
Prognosis
Reverse Transcriptase Polymerase Chain Reaction
RNA, Neoplasm - genetics
RNA, Neoplasm - metabolism
Survival Analysis
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endostatin, a M r 20,000 COOH-terminal fragment of collagen XVIII, is currently in preclinical development as a novel antiangiogenic agent. The gene expression of this molecule in 23 normal ovaries with follicle or corpus luteum and in 64 cases of epithelial ovarian cancer (27 serous, 18 mucinous, 13 endometrioid, 4 clear cell, and 2 undifferentiated carcinomas) was analyzed by PCR of RNA after reverse transcription. Seven of the cases were of low malignant potential. With regard to staging, 23 cases had stage I disease, 5 had stage II disease, 29 had stage III disease, and 7 had stage IV disease. The level of endostatin gene expression was described in terms of the ratio of the relative yield of the endostatin gene to that of the β 2-microglobulin gene. Endostatin gene expression in ovarian cancers (median, 0.14; range, 0.02–1.11) was significantly higher than that in normal ovaries with follicle or corpus luteum (median, 0.08; range, 0.03–0.26; P = 0.009). International Federation of Gynecology and Obstetrics stage ( P = 0.009) and residual tumor ( P = 0.005) were significantly associated with endostatin gene expression; however, other clinicopathological features ( e.g. , patient age at diagnosis, histological subtype, and histological grade) were not significantly associated with endostatin gene expression. Survival data were available for all patients. Univariate Cox regression analysis showed the prognosis of the patients with high endostatin gene expression [equal to or greater than the median (≥0.14)] to be significantly worse than that of patients with low endostatin gene expression [less than the median (
ISSN:1078-0432
1557-3265